CA3085255A1 - Eif4e-inhibiting compounds and methods - Google Patents

Eif4e-inhibiting compounds and methods Download PDF

Info

Publication number
CA3085255A1
CA3085255A1 CA3085255A CA3085255A CA3085255A1 CA 3085255 A1 CA3085255 A1 CA 3085255A1 CA 3085255 A CA3085255 A CA 3085255A CA 3085255 A CA3085255 A CA 3085255A CA 3085255 A1 CA3085255 A1 CA 3085255A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
mmol
cancer
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3085255A
Other languages
English (en)
French (fr)
Inventor
Samuel Sperry
Alan X. Xiang
Justin T. Ernst
Siegfried H. Reich
Mike SHAGHAFI
Theo Michels
Christian NILEWSKI
Chinh Viet Tran
Garrick Kenneth Packard
Alan Grubbs
Kaveri URKALAN
Takasuke MUKAIYAMA
Paul A. Sprengeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Effector Therapeutics Inc
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of CA3085255A1 publication Critical patent/CA3085255A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3085255A 2019-07-02 2020-06-30 Eif4e-inhibiting compounds and methods Pending CA3085255A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
US62/869662 2019-07-02

Publications (1)

Publication Number Publication Date
CA3085255A1 true CA3085255A1 (en) 2021-01-02

Family

ID=71614984

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3188446A Pending CA3188446A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
CA3085255A Pending CA3085255A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting compounds and methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3188446A Pending CA3188446A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Country Status (14)

Country Link
US (2) US11286268B1 (ko)
EP (1) EP3994139A1 (ko)
JP (1) JP2022539256A (ko)
KR (1) KR20220061945A (ko)
CN (1) CN114269756B (ko)
AR (1) AR119339A1 (ko)
AU (1) AU2020299362A1 (ko)
BR (1) BR112021026682A2 (ko)
CA (2) CA3188446A1 (ko)
CL (1) CL2021003573A1 (ko)
IL (1) IL289456A (ko)
TW (1) TWI748541B (ko)
UY (1) UY38773A (ko)
WO (1) WO2021003157A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
AU2021405409A1 (en) 2020-12-22 2023-07-06 Effector Therapeutics, Inc. Solid forms of an eif4e inhibitor
WO2024103069A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
CN118239963A (zh) * 2022-12-23 2024-06-25 南京圣和药业股份有限公司 作为eIF4E抑制剂的化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014179237A1 (en) * 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1
AU2015213721B2 (en) 2014-02-07 2021-05-20 Effector Therapeutics, Inc. Methods for treating fibrotic disease
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法

Also Published As

Publication number Publication date
CL2021003573A1 (es) 2022-08-12
KR20220061945A (ko) 2022-05-13
IL289456A (en) 2022-02-01
CN114269756B (zh) 2024-05-14
US20230108594A1 (en) 2023-04-06
TW202115058A (zh) 2021-04-16
WO2021003157A1 (en) 2021-01-07
BR112021026682A2 (pt) 2022-03-15
CA3188446A1 (en) 2021-01-07
US11286268B1 (en) 2022-03-29
UY38773A (es) 2021-01-29
JP2022539256A (ja) 2022-09-07
AU2020299362A1 (en) 2022-02-24
CN114269756A (zh) 2022-04-01
AR119339A1 (es) 2021-12-09
EP3994139A1 (en) 2022-05-11
TWI748541B (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
US9814718B2 (en) MNK inhibitors and methods related thereto
CA3085255A1 (en) Eif4e-inhibiting compounds and methods
EP3888658B1 (en) Eif4-a-inhibiting compounds and methods related thereto
CA2927252C (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10988476B2 (en) Substituted pyrimidines as cyclin-dependent kinase inhibitors
TWI499420B (zh) 肌醇磷脂３-激酶抑制劑化合物及使用方法
CN117304191A (zh) 作为a2a/a2b抑制剂的稠合吡嗪衍生物
KR102677015B1 (ko) Bet 억제제로서의 헤테로시클릭 화합물
CA3002877A1 (en) Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
TW202023559A (zh) 吡化合物及其用途
JP6888006B2 (ja) Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
BRPI1012159A2 (pt) derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase.
JP2022526831A (ja) ヘテロ環式化合物およびその使用
AU2022383957A1 (en) Thiophene ulk1/2 inhibitors and their use thereof
CN115181092B (zh) 吡嗪化合物和其用途
WO2023215494A1 (en) Thiophene ulk1/2 inhibitors and their use thereof
TW201305153A (zh) 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240313